Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
The question is if the drug worked so well, why did company employees have to manipulate the data per the SEC? I personally would sell into any rally. Jmho
If the trial fails can you imagine the class action?
Man it's getting close!
Thanks for this. It's a very well thought out theory based on a large number of patients in studies. I think it could play a role in the success or failure of Sava's drug later this year. Hoping for a positive outcome
From this evening's 6K. No idea if it's BS or not.
NeuroSense Therapeutics Ltd. (the Company) hereby reports that it is currently in advanced discussions with several multi-billion-dollar pharmaceutical companies regarding a potential strategic partnership for the development and commercialization of its lead drug candidate, PrimeC, for the treatment of Amyotrophic Lateral Sclerosis (ALS).
These discussions, based on non-binding terms, indicate the potential for substantial financial benefits to NeuroSense, including upfront payments, milestone payments and royalty payments as part of an agreement. NeuroSense anticipates receiving terms from these discussions in Q4 2024; however, there can be no assurance that terms will be finalized with any of the pharmaceutical companies, the timing, what would be the final terms, if any, or that a definitive agreement will be reached.
Per 10q company finally gained synthetic bioequivalence. Of course only matters if they start additional trials
Quite the ride here. Smart move
Money raise with .75 warrants attached fyi. Now we know why the price has remained so low IMO
Praying for success and in 5 short months we'll know one way or another. Never bet more than one can afford to lose
Nice move today for the bulls!
How would 30% of patients not being helped make for great results? And no 90% isn't unheard of. Does mean it's safe and that's why FDA hasn't stopped trials even with company management stepping down or indicted and is great news compared to MABs for sure
Thanks Doc! Hoping for the best here but 92% is just nuts!
The trials were designed before folks realized it doesn't work for moderate patients and included them in these current trials. No one believes there is 92% chance of successful trials. Least of which Wallstreet.
Not the right answer but it's OK. It will impact trial results. Folks should be aware of that and with the latest debacle folks may shoot first and ask questions later.
They aren't the only ones, no. And if everyone knew it wouldn't work for moderate then why include in the primary results?
Blame the boogeyman but don't respond to facts. Got it. Founding members of the company gone but blame it on the shorts?
You clearly know nothing about me but no nevermind. Keep running AI "research" and pretending to not understand that moderate patients did even worse than expected in P2 and many were included in the current P3. Cross your fingers and don't gamble more than you can afford to lose
I know the answers. Apparently some don't. AI is useless evaluating a drug for a disease that no one completely understands. Read my post from February 7. It is much more telling than anything AI can spit out IMO. GL
What mmse scores were allowed in these current trials? What did the bottom range of those score in 2B trials? Scoring range was too broad but not known until too late for current trial recruitment.
There were mistakes with how the current trial was set up that will likely keep the primary endpoints from being met. There will be explanations for the miss, perhaps valid. Problem now will be that wall street will now have an excuse, and so will the FDA for that matter. Now that's just my opinion but for sure based on 2B studies, the current trials recruited patients from too broad of a scoring spectrum.
Believe me I hope the drug works but today was hard for me to believe
Imo there has never been a more true binary outcome for a pre-revenue biotech than for shareholders here with current trial P3 results. This thing will go to near zero if end of year results don't meet primary endpoints. If results drag out past early January pretty much the same thing is my guess. Credibility is near zero and very fortunate the trials are so far along
What statistical significance level was that?
Yeah I've just been a follower for a couple years. Glad the trial will run it's course in case the drug does work but what a debacle
Quite the corporate shake up. Any thoughts?
Who knows? Unless you are trading the stock, real results are a long ways off IMO and that can lead to opportunity cost. If it's a small percentage of a speculative portfolio the current price probably isn't bad. Just depends on your patience level
The data is good but they'll have to raise money for a P3 so these guys are still a ways off IMO. They've mentioned a potential Biogen partnership last year yet here we stand. I do believe the drug is safe and has a real chance. Timing is everything.
Great data out. On to P3. Only thing that will likely sustain share price after this rally is partnership IMO.
Thanks Doc. Yes more of an interest in the science at this point and sounds like even that's a long way off.
Haven't owned shares in a long time but so glad these guys already recruited these trials.
Wow SAVA getting killed today
Not looking good today. Down bad
I do like the advanced MRI imaging for biomarkers. Could help in future AD studies hopefully. More science and less guess work.
It's good news. A bit delayed. Cleveland Clinic will run the trial and it will take a couple years. Doc would be a good one to comment as I believe this is his area of expertise. I would love to see an IND for FragileX but not sure of it's status if any. Seemingly telling that company hasn't mentioned AD in a long time.
Read the filings
Shocker...and some claimed nearly 2 years cash in the bank lol. Large debt on the books.
125 million....that's real money. Brilliant strategy from company management it would seem to me. 6ish months to go!
Agreed
Yeah I like COYA as well. NRSN put out additional results this morning showing a positive trend that hopefully allows a successful P3 trial in ALS as well.
Certainly showing a positive trend on the scientific front.
https://ih.advfn.com/stock-market/NASDAQ/neurosense-therapeutics-NRSN/stock-news/93791685/neurosense-announces-new-positive-data-analysis-fr